Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
2.

Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update.

Westermann A, Mella O, Van Der Zee J, Jones EL, Van Der Steen-Banasik E, Koper P, Uitterhoeve AL, De Wit R, Van Der Velden J, Burger C, Schem BC, Van Der Wilt C, Dahl O, Prosnitz LR, Van Tinteren H.

Int J Hyperthermia. 2012;28(6):549-53. doi: 10.3109/02656736.2012.673047. Epub 2012 Jul 13.

PMID:
22788973
3.

Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin.

Codacci-Pisanelli G, Noordhuis P, van der Wilt CL, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):733-9. doi: 10.1080/15257770802145496.

PMID:
18600533
4.

CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.

Hubeek I, Comijn EM, Van der Wilt CL, Merriman RL, Padron JM, Kaspers GJ, Peters GJ.

Oncol Rep. 2008 Jun;19(6):1517-23.

PMID:
18497959
5.

First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma.

Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der Velden J, Burger C, van der Wilt CL, Dahl O, Prosnitz LR, van der Zee J.

Cancer. 2005 Aug 15;104(4):763-70.

6.

A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.

Noordhuis P, Holwerda U, Van Laar JA, Van der Wilt CL, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1481-4.

PMID:
15571281
7.

Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.

Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, Talianidis I, Peters GJ.

Biochem Pharmacol. 2004 Aug 15;68(4):601-9.

PMID:
15276067
8.

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.

Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM, Peters GJ.

Ann Oncol. 2004 Jul;15(7):1025-32.

PMID:
15205195
9.

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ.

Br J Cancer. 2003 Jun 16;88(12):1963-70.

10.

Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.

van der Wilt CL, Kroep JR, Loves WJ, Rots MG, Van Groeningen CJ, Kaspers GJ, Peters GJ.

Eur J Cancer. 2003 Mar;39(5):691-7.

PMID:
12628850
11.

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ.

Mol Cancer Ther. 2002 Apr;1(6):371-6.

12.

Effects of antifolates on the binding of 5-fluoro-2'-deoxyuridine monophosphate to thymidylate synthase.

van der Wilt CL, Smid K, Peters GJ.

Biochem Pharmacol. 2002 Aug 15;64(4):669-75.

PMID:
12167486
13.

High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.

Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters GJ.

Oncology. 2002;62(4):363-70.

PMID:
12138245
14.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. Review.

15.

Thymidylate synthase inhibition induces p53 dependent and independent cell death.

Backus HH, Wouters D, van der Wilt CL, Kuiper CM, van Groeningen CJ, Pinedo HM, Peters GJ.

Adv Exp Med Biol. 2000;486:303-6. No abstract available.

PMID:
11783505
16.

The role of deoxycytidine kinase in gemcitabine cytotoxicity.

van der Wilt CL, Kroep JR, Bergman AM, Loves WJ, Alvarez E, Talianidis I, Eriksson S, van Groeningen CJ, Pinedo HM, Peters GJ.

Adv Exp Med Biol. 2000;486:287-90. No abstract available.

PMID:
11783501
17.

Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ.

Cancer Res. 2001 May 1;61(9):3675-81.

18.

The multilayered postconfluent cell culture as a model for drug screening.

Padrón JM, van der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HH, Pizao PE, Giaccone G, Peters GJ.

Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):141-57. Review.

PMID:
11033303
19.

Basis for effective combination cancer chemotherapy with antimetabolites.

Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP.

Pharmacol Ther. 2000 Aug-Sep;87(2-3):227-53. Review.

PMID:
11008002
20.

Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.

Backus HH, Pinedo HM, Wouters D, Padrón JM, Molders N, van Der Wilt CL, van Groeningen CJ, Jansen G, Peters GJ.

Int J Cancer. 2000 Sep 15;87(6):771-8.

21.

Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.

van der Wilt CL, Kuiper CM, Peters GJ.

Oncol Res. 1999;11(8):383-91.

PMID:
10803742
22.
23.

5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.

Kralovánszky J, Katona C, Jeney A, Pandi E, Noordhuis P, Erdélyi-Tóth V, Otvös L, Kovács P, Van der Wilt CL, Peters GJ.

J Cancer Res Clin Oncol. 1999 Dec;125(12):675-84.

PMID:
10592100
24.

Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.

Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.

Anticancer Drugs. 1999 Jun;10(5):445-52.

PMID:
10477163
25.

Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives.

Peters GJ, Voorn DA, Kuiper CM, van der Wilt CL, Noordhuis P, Smid K, Myhren F, Sandvold M, Hendriks HR.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):877-8.

PMID:
10432699
26.

Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.

van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ.

Clin Cancer Res. 1999 Mar;5(3):643-54.

27.

Determinants of the therapeutic efficacy of thymidylate synthase inhibitors.

Peters GJ, Kuiper CM, van Triest B, Backus H, van der Wilt CL, van Laar JA, Jansen G, van Groeningen CJ, Pinedo HM.

Adv Exp Med Biol. 1998;431:699-704. No abstract available.

PMID:
9598155
28.

The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil.

van der Wilt CL, Smid K, Veerman G, Peters GJ.

Adv Exp Med Biol. 1998;431:653-6. No abstract available.

PMID:
9598146
29.

Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.

van Triest B, Pinedo HM, Telleman F, van der Wilt CL, Jansen G, Peters GJ.

Biochem Pharmacol. 1997 Jun 15;53(12):1855-66.

PMID:
9256160
30.

Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells.

van der Wilt CL, Smid K, Aherne GW, Noordhuis P, Peters GJ.

Eur J Cancer. 1997 Mar;33(3):471-8.

PMID:
9155534
31.

Modulation of 5-fluorouracil in mice using uridine diphosphoglucose.

Codacci-Pisanelli G, Kralovanszky J, van der Wilt CL, Noordhuis P, Colofiore JR, Martin DS, Franchi F, Peters GJ.

Clin Cancer Res. 1997 Feb;3(2):309-15.

32.

5-fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man.

van der Wilt CL, van Groeningen CJ, Pinedo HM, Smid K, Hoekman K, Meijer S, Peters GJ.

J Cancer Res Clin Oncol. 1997;123(11-12):595-601. Erratum in: J Cancer Res Clin Oncol 1998;124(2):130.

PMID:
9620216
33.

Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.

van Laar JA, van der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM, Peters GJ.

Clin Cancer Res. 1996 Aug;2(8):1327-33.

34.
35.

Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.

Van Laar JA, Rustum YM, Van der Wilt CL, Smid K, Kuiper CM, Pinedo HM, Peters GJ.

Cancer Chemother Pharmacol. 1996;39(1-2):79-89.

PMID:
8995503
36.

The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.

Jansen WJ, Pinedo HM, van der Wilt CL, Feller N, Bamberger U, Boven E.

Eur J Cancer. 1995 Dec;31A(13-14):2313-9. Erratum in: Eur J Cancer 1996 Jan;32A(1):185.

PMID:
8652262
37.

Thymidylate synthase as a target in cancer chemotherapy.

Peters GJ, van der Wilt CL.

Biochem Soc Trans. 1995 Nov;23(4):884-8. No abstract available.

PMID:
8654859
38.

The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531.

Schuurman B, Sirovich I, Heuff G, van der Wilt CL, Peters GJ, Beelen RH, Meyer S.

J Surg Oncol. 1995 Nov;60(3):180-4.

PMID:
7475068
39.

Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay.

Peters GJ, Noordhuis P, Komissarov A, Holwerda U, Kok M, Van Laar JA, Van der Wilt CL, Van Groeningen V, Pinedo HM.

Anal Biochem. 1995 Oct 10;231(1):157-63.

PMID:
8678295
40.

Thymidylate synthase and drug resistance.

Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1299-305. Review.

PMID:
7577040
41.

Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect?

Van der Wilt CL, Braakhuis BJ, Pinedo HM, De Jong M, Smid K, Peters GJ.

Int J Cancer. 1995 May 29;61(5):672-8.

PMID:
7768641
42.

Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity.

van der Wilt CL, Cloos J, de Jong M, Pinedo HM, Peters GJ.

Oncol Res. 1995;7(6):317-21.

PMID:
8527866
43.

The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat.

van der Wilt CL, Marinelli A, Pinedo HM, Cloos J, Smid K, van de Velde CJ, Peters GJ.

Eur J Cancer. 1995;31A(5):754-60.

PMID:
7640050
44.

Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.

Codacci-Pisanelli G, van der Wilt CL, Pinedo HM, Franchi F, Noordhuis P, Braakhuis BJ, van Laar JA, Peters GJ.

Eur J Cancer. 1995;31A(9):1517-25.

PMID:
7577082
45.

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil.

Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM.

J Clin Oncol. 1994 Oct;12(10):2035-42.

PMID:
7931471
46.

New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

van der Wilt CL, Peters GJ.

Pharm World Sci. 1994 Apr 15;16(2):84-103. Review. Erratum in: Pharm World Sci 1994 Jun 10;16(3):167.

PMID:
7518280
47.

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase.

Peters GJ, van der Wilt CL, van Groeningen CJ.

Eur J Cancer. 1994;30A(10):1408-11. Review. No abstract available.

PMID:
7833092
48.

Cross-resistance to thymidylate synthase inhibitors in P-glycoprotein and non-P-glycoprotein cell lines.

van Triest B, Telleman F, Pinedo HM, van der Wilt CL, Peters GJ.

Adv Exp Med Biol. 1994;370:189-93. No abstract available.

PMID:
7660887
49.

Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase.

van der Wilt CL, van Laar JA, Smid K, Rustum YM, Peters GJ.

Adv Exp Med Biol. 1994;370:109-14. No abstract available.

PMID:
7660870
50.

In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.

van der Wilt CL, Visser GW, Braakhuis BJ, Wedzinga R, Noordhuis P, Smid K, Peters GJ.

Br J Cancer. 1993 Oct;68(4):702-7.

Supplemental Content

Loading ...
Support Center